Based on the Astria Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Astria Therapeutics Inc is USD 21.30 over the next 12 months. Astria Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Astria Therapeutics Inc is Bearish, which is based on 1 positive signals and 4 negative signals. At the last closing, Astria Therapeutics Inc’s stock price was USD 7.46. Astria Therapeutics Inc’s stock price has changed by -11.92% over the past week, -21.64% over the past month and +6.72% over the last year.
No recent analyst target price found for Astria Therapeutics Inc
No recent average analyst rating found for Astria Therapeutics Inc
Company Overview Astria Therapeutics Inc
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. Read Less
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma ka...Read More
Frequently Asked Questions About Astria Therapeutics Inc (ATXS) Stock
Based on ratings from 5 analysts Astria Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATXS's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ATXS is USD 21.30 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on ATXS's stock to indicate if its overvalued.
The last closing price of ATXS's stock was USD 7.46.
The most recent market capitalization for ATXS is USD 0.50B.
Based on targets from 5 analysts, the average taret price for ATXS is projected at USD 21.30 over the next 12 months.
This means that ATXS's stock price may go up by +185.52% over the next 12 months.
We can't find any ETFs which contains Astria Therapeutics Inc's stock.
As per our most recent records Astria Therapeutics Inc has 59 Employees.
Astria Therapeutics Inc's registered address is 75 State Street, Boston, MA, United States, 02109.
You can get more information about it from Astria Therapeutics Inc's website at https://www.astriatx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Astria Therapeutics Inc (ATXS) Stock
Based on ratings from 5 analysts Astria Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 10 buy, sell and hold ratings.
Unfortunately we do not have enough data on ATXS's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for ATXS is USD 21.30 over the next 12 months. The maximum analyst target price is USD 28 while the minimum anlayst target price is USD 16.
Unfortunately we do not have enough data on ATXS's stock to indicate if its overvalued.
The last closing price of ATXS's stock was USD 7.46.
The most recent market capitalization for ATXS is USD 0.50B.
Based on targets from 5 analysts, the average taret price for ATXS is projected at USD 21.30 over the next 12 months.
This means that ATXS's stock price may go up by +185.52% over the next 12 months.
We can't find any ETFs which contains Astria Therapeutics Inc's stock.
As per our most recent records Astria Therapeutics Inc has 59 Employees.
Astria Therapeutics Inc's registered address is 75 State Street, Boston, MA, United States, 02109.
You can get more information about it from Astria Therapeutics Inc's website at https://www.astriatx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATXS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
